Historical abbv News Stories
AbbVie Boosted by Obesity Data, API Investment Now
AbbVie gained concrete catalysts this week: positive Phase 1 ABBV‑295 weight‑loss data, a $380M API facility investment, and an FDA nod for a VENCLEXTA combination in first‑line CLL—each signaling tangible revenue and operational support for ABBV stock.
AbbVie Slides After J&J Psoriasis Pill Approval Q1
AbbVie (ABBV) shares fell to multi‑month lows after J&J’s FDA approval of oral psoriasis drug Icotyde and a 5th Circuit ruling on 340B discounts intensified margin and competitive pressures. Technical sell signals and recent debt activity add near‑term caution for investors.
AbbVie Raises $7.95B, Shares Show Resilience Today
AbbVie issued $7.95 billion in senior notes this week, a strategic capital move that coincided with steady share performance. Sector M&A and peer trial news are shaping investor sentiment for ABBV in the S&P 500.
AbbVie: SKYRIZI Win, Obesity Data, $380M Expansion
AbbVie saw multiple concrete catalysts this week: robust Phase 3 SKYRIZI data in Crohn’s disease, promising early weight‑loss results for ABBV‑295, a $380M API plant expansion in North Chicago, and mixed market signals from insider selling and steady valuation metrics. These events reinforce AbbVie’s transition away from Humira and underpin near‑term investor focus on clinical readouts, manufacturing capacity, and commercialization paths.
AbbVie’s Big Deals and $100B U.S. Investment Boost
This week AbbVie announced two landmark oncology licensing deals (Zelgen and RemeGen), reported robust full‑year 2025 results with $61.16B revenue, and committed $100B to U.S. R&D and capital investment tied to a voluntary pricing agreement—concrete moves that materially affect ABBV stock outlook.
AbbVie Builds U.S. API Hubs, Raises $7.5B Debt Now!
AbbVie announced a $380M investment to expand API manufacturing in North Chicago and launched a $7.5B senior notes offering to refinance upcoming debt. These concrete moves — combined with mixed Q4 results driven by Humira strength and Rinvoq softness — reshape ABBV's operational and financial outlook for investors.
AbbVie Q4: Skyrizi & Rinvoq Drive 2026 Outlook Now
AbbVie's Q4/FY2025 results show continued strength from Skyrizi and Rinvoq, lifting immunology and neuroscience sales even as aesthetics lag. Management issued clear 2026 adjusted EPS guidance; near-term shares retraced modestly on low volume.
AbbVie Boosts U.S. Ties with $100B Investment Deal
AbbVie stock climbed on heavy volume after the company struck a voluntary $100 billion U.S. investment agreement and continued to benefit from immunology patent protections. These moves strengthen manufacturing footholds, regulatory optics, and revenue durability for ABBV shareholders.
AbbVie Q4 Beat, Stock Drops on Humira Risk
AbbVie reported a modest Q4 beat (EPS $2.71 vs $2.65; revenue $16.62B vs $16.41B) but shares fell ~3.8% as investors focused on Humira erosion and mixed performance from growth brands. Elevated trading volume and limited new regulatory catalysts leave ABBV exposed to pipeline execution and pricing pressures despite Rinvoq’s prior GCA approval.